Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety, tolerability, and
pharmacokinetic (PK) profile of 3 intravenous (IV) injections of BG00010 given on 2 fixed
schedules; weekly and as frequently as every 48 hours (but no more than 3 times per week).
Secondary objectives of this study in this study population are to explore the repeated-dose
immunogenicity of BG00010 and to explore the potential of BG00010 to reduce pain following
multiple-dose administration.